Skip to main content
Top
Published in: Journal of Gastrointestinal Cancer 4/2019

01-12-2019 | Original Research

Acute Portal Vein Thrombosis Predicts Concomitant Diagnosis of Hepatocellular Carcinoma in Cirrhotic Patients

Authors: Tawfik Khoury, Muhammad Massarwa, Wadi Hazou, Saleh Daher, David Hakimian, Ariel A. Benson, Toni Ashqar, Mahmud Mahamid, Shaul Yaari

Published in: Journal of Gastrointestinal Cancer | Issue 4/2019

Login to get access

Abstract

Purpose

Portal vein thrombosis (PVT) is a common condition in cirrhotic patients and mostly attributed to portal hypertension. The objective of our study was to examine the association of PVT with hepatocellular carcinoma (HCC) in cirrhotic patients.

Methods

A retrospective study was performed to identify cirrhotic patients with thrombosis of the portal system. Clinical and laboratory characteristics were collected and analyzed.

Results

Thirty-nine patients were identified. Twenty-four out of 39 patients with PVT did not develop HCC (group A) after follow-up time of 38.5 months from the diagnosis of PVT. Eight patients (20.5%) were diagnosed with HCC within two weeks following diagnosis of PVT (group B). Seven patients (17.9%) were diagnosed with tumor thrombus (group C) at time of PVT diagnosis. The average age was 53.5, 66.5, and 69 years for groups A, B, and C respectively. Most patients (75 and 87.5% for groups B and C respectively) diagnosed with PVT and HCC were males. The most common cause of cirrhosis in groups B and C was chronic hepatitis B virus infection (HBV) in 62.5% and 50% respectively. The most common clinical presentation of PVT in group A was abdominal pain in 55.5% compared to new/worsening ascites in 43% and 37.5% for groups B and C respectively. The platelet count in groups B and C was higher as compared to that in group A (126 and 125 vs. 107 thousand, P = NS).

Conclusion

In 38.4% of cases, new diagnosis of PVT was associated with concomitant diagnosis of HCC. Identifiable risk factors were chronic HBV infection and higher platelet count.
Literature
1.
go back to reference Francoz C, Belghiti J, Vilgrain V, Sommacale D, Paradis V, Condat B, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut. 2005;54(5):691–7.CrossRef Francoz C, Belghiti J, Vilgrain V, Sommacale D, Paradis V, Condat B, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut. 2005;54(5):691–7.CrossRef
2.
go back to reference Tripodi A, et al. Hypercoagulability in cirrhosis: causes and consequences. J Thromb Haemost. 2011;9(9):1713–23.CrossRef Tripodi A, et al. Hypercoagulability in cirrhosis: causes and consequences. J Thromb Haemost. 2011;9(9):1713–23.CrossRef
3.
go back to reference Zocco MA, di Stasio E, de Cristofaro R, Novi M, Ainora ME, Ponziani F, et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol. 2009;51(4):682–9.CrossRef Zocco MA, di Stasio E, de Cristofaro R, Novi M, Ainora ME, Ponziani F, et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol. 2009;51(4):682–9.CrossRef
4.
go back to reference Bechmann LP, Wichert M, Kröger K, Hilgard P. Dosing and monitoring of low-molecular-weight heparin in cirrhotic patients. Liver Int. 2011;31(7):1064.CrossRef Bechmann LP, Wichert M, Kröger K, Hilgard P. Dosing and monitoring of low-molecular-weight heparin in cirrhotic patients. Liver Int. 2011;31(7):1064.CrossRef
5.
go back to reference Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011;365(2):147–56.CrossRef Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011;365(2):147–56.CrossRef
6.
go back to reference Hollestelle MJ, Geertzen HG, Straatsburg IH, van Gulik T, van Mourik J. Factor VIII expression in liver disease. Thromb Haemost. 2004;91(2):267–75.CrossRef Hollestelle MJ, Geertzen HG, Straatsburg IH, van Gulik T, van Mourik J. Factor VIII expression in liver disease. Thromb Haemost. 2004;91(2):267–75.CrossRef
7.
go back to reference Biagini MR, Tozzi A, Marcucci R, Paniccia R, Fedi S, Milani S, et al. Hyperhomocysteinemia and hypercoagulability in primary biliary cirrhosis. World J Gastroenterol. 2006;12(10):1607–12.CrossRef Biagini MR, Tozzi A, Marcucci R, Paniccia R, Fedi S, Milani S, et al. Hyperhomocysteinemia and hypercoagulability in primary biliary cirrhosis. World J Gastroenterol. 2006;12(10):1607–12.CrossRef
8.
go back to reference Mangia A, Margaglione M, Cascavilla I, Gentile R, Cappucci G, Facciorusso D, et al. Anticardiolipin antibodies in patients with liver disease. Am J Gastroenterol. 1999;94(10):2983–7.CrossRef Mangia A, Margaglione M, Cascavilla I, Gentile R, Cappucci G, Facciorusso D, et al. Anticardiolipin antibodies in patients with liver disease. Am J Gastroenterol. 1999;94(10):2983–7.CrossRef
9.
go back to reference Qi X, Han G, Fan D. Management of portal vein thrombosis in liver cirrhosis. Nat Rev Gastroenterol Hepatol. 2014;11(7):435–46.CrossRef Qi X, Han G, Fan D. Management of portal vein thrombosis in liver cirrhosis. Nat Rev Gastroenterol Hepatol. 2014;11(7):435–46.CrossRef
10.
go back to reference Primignani M. Portal vein thrombosis, revisited. Dig Liver Dis. 2010;42(3):163–70.CrossRef Primignani M. Portal vein thrombosis, revisited. Dig Liver Dis. 2010;42(3):163–70.CrossRef
11.
go back to reference Mangia A, Villani MR, Cappucci G, Santoro R, Ricciardi R, Facciorusso D, et al. Causes of portal venous thrombosis in cirrhotic patients: the role of genetic and acquired factors. Eur J Gastroenterol Hepatol. 2005;17(7):745–51.CrossRef Mangia A, Villani MR, Cappucci G, Santoro R, Ricciardi R, Facciorusso D, et al. Causes of portal venous thrombosis in cirrhotic patients: the role of genetic and acquired factors. Eur J Gastroenterol Hepatol. 2005;17(7):745–51.CrossRef
12.
go back to reference Bruix J, Sherman M, D. American Association for the Study of Liver. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2.CrossRef Bruix J, Sherman M, D. American Association for the Study of Liver. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2.CrossRef
13.
go back to reference Llado L, et al. Management of portal vein thrombosis in liver transplantation: influence on morbidity and mortality. Clin Transpl. 2007;21(6):716–21. Llado L, et al. Management of portal vein thrombosis in liver transplantation: influence on morbidity and mortality. Clin Transpl. 2007;21(6):716–21.
14.
go back to reference DeLeve LD, et al. Vascular disorders of the liver. Hepatology. 2009;49(5):1729–64.CrossRef DeLeve LD, et al. Vascular disorders of the liver. Hepatology. 2009;49(5):1729–64.CrossRef
15.
go back to reference Shah V. Molecular mechanisms of increased intrahepatic resistance in portal hypertension. J Clin Gastroenterol. 2007;41(Suppl 3):S259–61.CrossRef Shah V. Molecular mechanisms of increased intrahepatic resistance in portal hypertension. J Clin Gastroenterol. 2007;41(Suppl 3):S259–61.CrossRef
16.
go back to reference Lertpipopmetha K, Auewarakul CU. High incidence of hepatitis B infection-associated cirrhosis and hepatocellular carcinoma in the Southeast Asian patients with portal vein thrombosis. BMC Gastroenterol. 2011;11:66.CrossRef Lertpipopmetha K, Auewarakul CU. High incidence of hepatitis B infection-associated cirrhosis and hepatocellular carcinoma in the Southeast Asian patients with portal vein thrombosis. BMC Gastroenterol. 2011;11:66.CrossRef
17.
go back to reference Maruyama H, Okugawa H, Takahashi M, Yokosuka O. De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes. Am J Gastroenterol. 2013;108(4):568–74.CrossRef Maruyama H, Okugawa H, Takahashi M, Yokosuka O. De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes. Am J Gastroenterol. 2013;108(4):568–74.CrossRef
18.
go back to reference Lisman T, Porte RJ. The role of platelets in liver inflammation and regeneration. Semin Thromb Hemost. 2010;36(2):170–4.CrossRef Lisman T, Porte RJ. The role of platelets in liver inflammation and regeneration. Semin Thromb Hemost. 2010;36(2):170–4.CrossRef
19.
go back to reference John BV, Konjeti R, Aggarwal A, Lopez R, Atreja A, Miller C, et al. Impact of untreated portal vein thrombosis on pre and post liver transplant outcomes in cirrhosis. Ann Hepatol. 2013;12(6):952–8.CrossRef John BV, Konjeti R, Aggarwal A, Lopez R, Atreja A, Miller C, et al. Impact of untreated portal vein thrombosis on pre and post liver transplant outcomes in cirrhosis. Ann Hepatol. 2013;12(6):952–8.CrossRef
Metadata
Title
Acute Portal Vein Thrombosis Predicts Concomitant Diagnosis of Hepatocellular Carcinoma in Cirrhotic Patients
Authors
Tawfik Khoury
Muhammad Massarwa
Wadi Hazou
Saleh Daher
David Hakimian
Ariel A. Benson
Toni Ashqar
Mahmud Mahamid
Shaul Yaari
Publication date
01-12-2019
Publisher
Springer US
Published in
Journal of Gastrointestinal Cancer / Issue 4/2019
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-018-0149-5

Other articles of this Issue 4/2019

Journal of Gastrointestinal Cancer 4/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine